The average twelve-month target price among analysts that have covered the stock in the last year is $8.3333. William Blair lowered Neogen from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 29th. Savant Capital LLC purchased a new position in shares of Neogen during the second quarter worth about $50,000. Lindenwold Advisors INC purchased a new position in shares of Neogen during the first quarter worth about $92,000. Finally, Cresset Asset Management LLC purchased a new position in shares of Neogen during the second quarter worth about $53,000.